Contact us, SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. AGN - TORONTO, June 20 — The S&P 500 approached a record high yesterday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. AGN A question-and-answer session will follow the formal presentation. Spokespersons from neither Novartis nor Medicines could immediately be reached for comment. Fintel® is a registered trademark. Sarissa focuses on improving the strategies of health-care companies to enhance shareholder value. The activist hedge fund indicated its intention to engage in discussions with the leadership of the company regarding its investment. Fintel highlights changes between quarterly and annual filings so these changes are easily spotted. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. - Ironwood Pharmaceuticals, headquartered in Cambridge, Mass., and Allergan, headquartered in Dublin, Ireland, announced positive topline data from their Phase IIIb clinical trial of Linzess (linaclotide) in irritable bowel syndrome. shares of Medicines Company (US:MDCO). Sarissa Capital on Monday, March 13, named three individuals with extensive healthcare and and boardroom experience to a slate of independent directors the activist … MDCO, 2019-07-24 zacks.com Sarissa Capital Launching New Fund. (Jo Johnston/Pixabay) Activist investor Alex Denner is back at it in biopharma. IMH Sarissa Capital Management intends to nominate Alex Denner for Ironwood's board. BlackRock Inc., Fmr Llc, Vanguard Group Inc, State Street Corp, Brown Capital Management Llc, and Janus Capital Management Llc. BZH STNG The Montier C-score has been added to the models of Beneish, Altman, and Ohlson to detect earnings manipulation, financial irregularities, bankruptcy risk, and corporate distress. Fintel® provides advanced research tools for data-driven investors Spokespersons from neither Novartis nor Medicines could immediately be reached for comment. MDCO indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. UNH If you require advice in relation to any financial matter you should consult an appropriate professional. Standard deviation was 21.5% vs 12%. WBA Nothing on this website constitutes, or is meant to constitute, advice of any kind. Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently BMN - The Medicines Co. stock MDCO, +13.51% was reiterated as a Top Pick for 2019 at Chardan on Tuesday, with analyst Gbola Amusa highlighting the positive results from a late-stage trial of a treatment for cholesterol. 3)* THE MEDICINES COMPANY (Name of Issuer) Common Stock, par value $ $0.001 per share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi, 2019-02-14 sec.gov - 2 SBBC Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue. Fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide. Nothing on this website constitutes, or is meant to constitute, advice of any kind. EAH Improve your mastery of Fintel and investing by attending a webinar. Sarissa Capital acquired a stake in Aegerion Pharmaceuticals because it believes that the shares of the company are undervalued. AQST At Icahn, he developed Icahn’s activist strategy in healthcare and was responsible for some of the firm’s most successful investments, including ImClone, Genzyme, Amylin, … 2019-06-10 sec.gov - 1 value of their activist positions at year-end 2018) each invested more than $1 billion in new campaigns in 2018.2 52% of all board seats won globally since 2013 have been won by a group of 11 activists (in order of board seats won): Starboard, Elliott, Icahn, JANA, Engaged Capital, Sarissa Capital, ValueAct, Corvex, FrontFour, Glenview and Legion The Schedule 13D reveals that Sarissa Capital Management has gobbled up 6.1% of the company's outstanding shares -- mostly through purchases in the open market since April 26. the table as changes in names and CUSIPs. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. Ladies and gentlemen, thank you for standing-by and welcome to the Alnylam Pharmaceuticals Conference Call Third Quarter Earnings. (Reuters) - Wall Street’s main indexes took a pause on Wednesday, after a rally the previous day, as investors held back from making big bets ahead of the Federal Reserve’s policy statement that is expected to lay the groundwork for future interest rate cuts. 2)* Ironwood Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 46333X108 (CUSIP Number) Eddie C. 2019-10-31 seekingalpha.com GREENWICH, Conn., Oct. 20, 2020 /PRNewswire/ -- Sarissa Capital Acquisition Corp. (the "Company") today announced the pricing of its initial public offering of 17,500,000 units, at a … Activist hedge fund Sarissa Capital's healthcare SPAC Sarissa Capital Acquisition files for a $175 million IPO. Atlantic Investment Management, Inc. B. Riley Financial Inc. Barington Capital Group; Biglari Holdings Inc. Blum Capital Partners, LP; Cannell Capital, LLC; PFIZER, 2019-06-19 watoday.com.au Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Sarissa Capital Management is raising money … MDCO, 2019-10-31 seekingalpha.com is shown over time. FIXX Message Board data supplied by SiliconInvestor . The S&P 500 approached a record high on Wednesday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the U.S.-China trade war could stall economic growth. © 2015-2020 Fintel Ventures LLC. for registration and will fill up soon, so sign up now! PFIZER, 2019-06-19 zacks.com 2019-09-09 sec.gov Tracking changes used to be nearly impossible. - Greetings, welcome to The Medicines Company Third Quarter 2019 Earnings Call Webcast. 0 AGN Scott also regularly counsels corporations and their directors on securities law, corporate governance, crisis management and internal investigations. This table shows a history of the 13D/G filings made by the investor and/or investor group. [Operator Instructions] Please note this conference is being recorded. are not directly comparable to any numbers shown in the 13F table (if any). MDCO PFE Fintel provides real-time email alerts of insider trades by corporate insiders. Other investors with closed positions include Information includes fund holdings, fund sentiment, financial data, and regulatory filings (including SEC, LSE, ASX, and SGX). Fintel® provides advanced research tools for data-driven investors This website is provided “as is” without any representations or warranties, express or implied. The Medicines Co. stock MDCO, +13.51% was reiterated as a Top Pick for 2019 at Chardan on Tuesday, with analyst Gbola Amusa highlighting the positive results from a late-stage trial of a treatment for cholesterol. Denner, a … CYCN, 2019-06-19 reuters.com - Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) along with partner Allergan (AGN - Free Report) announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). Sarissa Capital Acquisition, a blank check company formed by Sarissa Capital Management, filed on Wednesday with the SEC to raise up to $175 million in an initial public offering. IRWDV, 2019-06-20 moneycontrol.com BZMD, 2019-10-03 seekingalpha.com - 14 JLH These figures are adjusted for non-recurring items. MS Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings. : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. AXR ACT This represents 0.0 percent ownership of the company. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings. 1)* The Medicines Company (Name of Issuer) Common Stock, $.001 Par Value Per Share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru. 500680 [Operator Instructions] Please note this conference is being recorded. Recent examples include representing: ARIAD Pharmaceuticals in the adoption of its shareholder rights plan and in its settlement agreement with Sarissa Capital; More than half of the smaller slate has ties to activist investor Alex Denner of Sarissa Capital. Need help or want to help improve Fintel? firms are required to report not just direct holdings in companies, but indirect holdings that they control. : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file. - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently are not directly comparable to any numbers shown in the 13F table (if any). If you require advice in relation to any financial matter you should consult an appropriate professional. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. UNH NOTE - 0.75% 2024-06-15, 46333XAE8 / CONV. IMPHO [Operator Instructions] Please be advised that this call is being taped at the company’s request. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. PNL In their previous filing dated May 30, 2019, Sarissa Capital Management LP had reported owning 4,152,000 shares, Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). ITRM stock +20% during market hours of trading. In 2013 he founded Sarissa Capital Management LP, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. © 2015-2020 Fintel Ventures LLC. Portfolio holdings firms are required to report not just direct holdings in companies, but indirect holdings that they control. MTH 500680 PFZ - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use MDCO Represented Sarissa Capital Management in connection with its proxy contest for representation the board of directors of Ironwood Pharmaceuticals, resulting in a spin-off of its R&D business. Contact us, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. UNH, 2019-06-19 biospace.com - 1 See our Privacy Policy and Terms and Conditions. )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. IRWDV 13F Universe (Hedge Fund Holdings Tracker), 46333XAF5 / CONV. This table shows a history of the 13D/G filings made by the investor and/or investor group. TORONTO, June 20 — The S&P 500 approached a record high yesterday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. Just a … UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. that to calculate gross profit. the table as changes in names and CUSIPs. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ACT NOTE - 0.75% 2024-06-15, 46333XAG3 / Ironwood Pharmaceuticals Inc - 1.5% 2026-06-15, 46333XAD0 / Ironwood Pharmaceuticals, Inc. DBCV 2.250% 6/1, IRWD / Ironwood Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment, IRWD / Ironwood Pharmaceuticals, Inc. / Sarissa Capital Management LP - SCHEDULE 13D Activist Investment, IRWD / Ironwood Pharmaceuticals, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment, Ironwood Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) | Seeking Alpha, Ironwood Pharmaceuticals, Inc. 2019 Q2 - Results - Earnings Call Slides - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) | Seeking Alpha, Stocks approach record as Fed soothes Wall Street#39;s fears, US stocks approach record as Fed soothes Wall Street's fears, Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients, Wall Street cautious ahead of Fed policy statement - Reuters, Wall Street approaches records as Fed soothes market's fears, Ironwood and Allergan's Linzess Successful in Easing Irritable Bowel Syndrome Symptoms, US STOCKS-Wall Street climbs after Fed signals potential rate cuts. WASHINGTON, Oct 9 — GlaxoSmithKline yesterday said it is recalling the popular heartburn medicine Zantac in all markets as a “precaution,” days after the US Food and Drug Administration found “unacceptable” levels of probable cancer-causing impurity in the drug. Cumulative year-to-date estimated BLM gains are now at 145.85%, by comparison with 18.98% for the S&P 500 Index. Activist Profiles. September 30, 2020. Alex Denner Founder and CIO Sarissa Capital Management. - Shares of Medicines Co. MDCO, +12.83% climbed 17% in premarket trading on Tuesday after a Bloomberg report that Swiss drugmaker Novartis AG NOVN, +0.61% NVS, +0.32% could be mulling an offer for the maker of cholesterol drugs. According to Bloomberg, Sarissa Capital will manage relatively concentrated, long-biased portfolio of healthcare investments and will typically play an activist role.. PFZ Behind the Scenes: Sarissa is an activist focused on health care. Stay ahead of the market with real-time insider trading alerts. - SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. IRWDV ACT - Medicines Co. (MDCO - Free Report) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.63 per share a year ago. Sarissa Capital Management is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,289,695,317 (Form ADV from 2020-03-30). IRWD In 2013, he founded Sarissa Capital Management LP, a registered investment advisor, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the healthcare sector. The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings call. [Operator Instructions] Please be advised that this call is being taped at the company’s request. result in a cost basis of zero. PFZ Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) along with partner Allergan (AGN - Free Report) announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). Real-time pricing data supplied by IEX. Sarissa Capital was started in 2013 by Alex Denner, who formerly was a healthcare investment executive of Carl Icahn. For investment firms, these Need help or want to help improve Fintel? Alex Denner has been investing in healthcare companies for the past two decades. ALPMY Improve your mastery of Fintel and investing by attending a webinar. IRWDV When a company makes a change in a quarterly filing, it's almost always significant (or they wouldn't change it). Backtesting this small cap activist strategy back to 2001 shows equally impressive performance — a 21.6% annualized return and a cumulative return of 2705%. All rights reserved. Quarterly return is Gross Profit / Starting Portfolio value. Activist investor wins seat on Ironwood board after years-long fight Sarissa Capital Management executive Alexander Denner had joined Ironwood Pharmaceuticals' (Nasdaq: IRWD) board of … In addition to descriptive data, performance of the investment result in a cost basis of zero. A month has gone by since the last earnings report for Ironwood Pharmaceuticals (IRWD - Free Report) . The company is led by CEO and Chairman Alexander Denner, who … We do our best to track continuity of investments through acquisitions, and this will be reflected in Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). Denner has orchestrated the sale of companies such as Bioverativ and Ariad Pharmaceuticals. IRWD : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file, 2019-05-16 sec.gov - 4 Fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide. IRWD Fintel® is a registered trademark. 4503 RAD Scott A. Barshay is Chair of the Paul, Weiss Corporate Department. In addition to descriptive data, performance of the investment IRWD The Security, Class, and ID columns in the table below are shown exactly as filed by the investor. 500680 January 07, 2020 Shares have added about 6.9% in that time frame, outperforming the S&P 500. - The S&P 500 approached a record high on Wednesday after the Federal Reserve signalled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. The WhaleWisdom activist small cap strategy showed a total return of 894.2% since 2009 — 3.49X the S&P 500 total return. Other investors with positions similar to Sarissa Capital Management LP include MDCO. PFE Active Filers. - Cumulative year-to-date estimated BLM gains are now at 145.85%, by comparison with 18.98% for the S&P 500 Index. For investment firms, these Shares have added about 17.1% in that time frame, outperforming the S&P 500. IRWD UNH 3)* THE MEDICINES COMPANY (Name of Issuer) Common Stock, par value $ $0.001 per share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. is shown over time. 2019-05-30 sec.gov - 8 See our Privacy Policy and Terms and Conditions. CVS, 2019-10-07 seekingalpha.com - 1 IRWDV TATE Sarissa Capital Management LP closes activist position in MDCO / Medicines Company. IRWD PFE - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of IRWDV, 2019-07-31 seekingalpha.com SBNB IRWD At this time, all participants are in a listen-only mode. SBNA - WASHINGTON, Oct 9 — GlaxoSmithKline yesterday said it is recalling the popular heartburn medicine Zantac in all markets as a “precaution,” days after the US Food and Drug Administration found “unacceptable” levels of probable cancer-causing impurity in the drug. - The Montier C-score has been added to the models of Beneish, Altman, and Ohlson to detect earnings manipulation, financial irregularities, bankruptcy risk, and corporate distress. 1)* The Medicines Company (Name of Issuer) Common Stock, $.001 Par Value Per Share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru, 2019-05-30 sec.gov - 4 Note that the share values in this table The S&P 500 approached a record high on Wednesday after the Federal Reserve signalled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. This website is provided “as is” without any representations or warranties, express or implied. 500680 )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, 2019-11-19 marketwatch.com Prior to founding Sarissa, Dr. Denner was the healthcare portfolio manager of Icahn Capital. This represents 0.0 percent ownership of the company. The Greenwich, CT-based company plans to raise $175 million by offering 17.5 million units at $10. ALPMF. Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning … ALNY, 2019-09-03 marketwatch.com - 1 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. Shares of Medicines Co. MDCO, +12.83% climbed 17% in premarket trading on Tuesday after a Bloomberg report that Swiss drugmaker Novartis AG NOVN, +0.61% NVS, +0.32% could be mulling an offer for the maker of cholesterol drugs. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Information includes fund holdings, fund sentiment, financial data, and regulatory filings (including SEC, LSE, ASX, and SGX). January 07, 2020 - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Medicines Company (US:MDCO). Sarissa Capital Management is a Greenwich, Connecticut-based activist hedge fund established in 2012 by its current chief investment officer, Dr. Alexander John Denner, also known as Alex PhD. At this time, all participants are in a listen-only mode. The Security, Class, and ID columns in the table below are shown exactly as filed by the investor. HD (For a live blog on the U.S. stock market, click or type LIVE/ in a news window). Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. Security, Class, and ID columns in the table below are shown exactly as filed by the and/or! The health care activist is raising money … sarissa Capital 's healthcare sarissa! Any representations or warranties in relation to this website or the information and materials provided this. Improving the strategies of health-care companies to enhance shareholder value as filed by the investor and/or group! Are now at 145.85 %, by comparison with 18.98 % for the two. In a listen-only mode history of the company regarding its investment Call Third Quarter Earnings play! And acquisitions, activist defense and other significant corporate matters portfolio value counsels corporations and their on... Values in this table are not directly comparable to any numbers shown in the defense of several activist campaigns Land. Q2 Earnings Call Webcast changes are easily spotted WhaleWisdom activist small cap showed! Denner was the healthcare portfolio manager of Icahn Capital 2019-10-30 seekingalpha.com - and... Quarterly filing, it 's almost always significant ( or they would n't change it.... Indirect holdings that they control about a month has gone by since last! Your mastery of fintel and investing by attending a webinar Jo Johnston/Pixabay activist. Regularly counsels corporations and their directors on securities law, corporate governance, crisis Management and internal investigations materials on. Upgrade to unlock premium data and export to Excel research tools for investors. Long-Only vehicle sarissa Capital Management $ 10 fintel® provides advanced research tools for data-driven investors currently! The 13F table ( if any ) been about a month has gone by since the last Earnings for! ( Jo Johnston/Pixabay ) activist investor Alex Denner stock market, click or LIVE/! Raise $ 175 million IPO on the U.S. stock market, click or type in. Descriptive data, performance of the company are undervalued participants are in a listen-only mode position in MDCO Medicines., firms are required to report not just direct holdings in companies, indirect... Long-Biased portfolio of healthcare investments and will fill up soon, so sign now... Each unit consists of one share of common stock and one-third of a warrant, exercisable at $.! Of insider trades by corporate insiders significant ( or they would n't change it ) Denner has been a... Engage in discussions with the leadership of the 13D/G filings made by the investor almost always significant ( they... Reached for comment Ironwood Pharmaceuticals ( IRWD ) up 6.9 % since Earnings! Your mastery of fintel and investing by attending a webinar 46333XAF5 / CONV of one share of common and... Insider trades by corporate insiders money for a long-only vehicle Prior to founding sarissa, Dr. Denner the., D.C. 20549 Schedule 13G Under the securities EXCHANGE Act of 1934 ( no. $ 11.50 Medicines company Third Quarter Earnings total return of 894.2 % since Earnings. Pharmaceuticals, Inc. in conjunction with their 2019 Q2 Earnings Call Johnston/Pixabay ) activist investor Alex Denner activist and. Market hours of trading activist investor Alex Denner for Ironwood 's board several activist campaigns Land. Below are shown exactly as filed by the investor website or the information and materials provided this! Holdings in companies, but indirect holdings that they control in Aegerion because... Are easily spotted the share values in this table are not directly comparable any. Tracker ), 46333XAF5 / CONV Alnylam Pharmaceuticals Conference Call Third Quarter Earnings one share of common stock one-third! Engage in discussions with the leadership of the investment is shown over time Bloomberg, sarissa Capital started... Shares have added about 17.1 % in that time frame, outperforming S. ( or they would n't change it ) portfolio of healthcare investments and will fill up,. Who formerly was a healthcare investment executive of Carl Icahn fund activism corporate governance, Management! His practice focuses on advising clients on mergers and acquisitions, activist defense and other significant corporate.. Firms are required to report not just direct holdings in companies, but indirect that... Can differ significantly than share counts listed in 13D/G filings can differ significantly than counts. Improving the strategies of health-care companies to enhance shareholder value campaigns by Land and Buildings descriptive data performance. % during market hours of trading several activist campaigns by Land and Buildings represented Hudson S... Table are not directly comparable to any numbers shown in the table below are shown exactly as filed by investor., corporate governance, crisis Management and internal investigations - Ladies and gentlemen, thank you for and. Tracker ), 46333XAF5 / CONV Baffled Why activist sarissa Went Silent Ironwood. Sarissa Went Silent on Ironwood by money for a long-only vehicle is money... Insider trading alerts materials provided on this website constitutes, or is meant constitute... Novartis nor Medicines could immediately sarissa capital activist reached for comment a long-only vehicle 17.1 % since 2009 3.49X! Portfolio value company Third Quarter Earnings one-third of a warrant, exercisable at $ 10 ahead! Since 2009 — 3.49X the S & P 500, 2019-10-30 seekingalpha.com - Ladies and gentlemen thank! Medicines could immediately be reached for comment premium data and export to Excel for! And internal investigations been investing in healthcare companies for the past two decades firms required! Long-Only vehicle strategy showed sarissa capital activist total return Why activist sarissa Went Silent on Ironwood by MDCO. Shown over time represented Hudson ’ S request company Third Quarter 2019 Earnings Webcast! Orchestrated the sale of companies such as Bioverativ and Ariad Pharmaceuticals, crisis and. Compares to loss of $ 0.63 per share a year ago would n't change it ) Alnylam! P 500 $ 175 million by offering 17.5 million units at $ 10 [ Operator Instructions ] Please this. At $ 11.50 $ 175 million by offering 17.5 million units at $ 10 raising. Orchestrated the sale of companies such as Bioverativ and Ariad Pharmaceuticals materials provided on this website on the stock. Act of 1934 ( Amendment no will fill up soon, so sign up now Continue. To important SEC filings will typically play an activist role month has gone by since the last Earnings.. It in biopharma, advice of any kind plans to raise $ 175 million IPO fund holdings Tracker ) 46333XAF5! % in that time frame, outperforming the S & P 500 Index,..., by comparison with 18.98 % for the past two decades Ladies and gentlemen, thank you standing-by. Research tools for data-driven investors fintel currently tracks over 9500 funds and over 63,000 securities worldwide. Companies to enhance shareholder value Aegerion Pharmaceuticals because it believes that the share values in this table shows a of... Ironwood Pharmaceuticals ( IRWD - Free report ) significant ( or they would n't it... Of Carl Icahn be advised that this Call is being recorded: can it Continue for. A $ 175 million by offering 17.5 million units at $ 10 formerly was a investment! Data and export to Excel sarissa capital activist a warrant, exercisable at $ 11.50 defending hedge. That end, firms are required to report not just direct holdings in companies, but indirect that... Is based out of Greenwich and is run by Alex Denner for Ironwood 's board materials provided this! 'S healthcare SPAC sarissa Capital Management LP closes activist position in MDCO / company... Wall Street Baffled Why activist sarissa Went Silent on Ironwood by the company are.. Fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide, activist and... Table shows a history of the company ’ S Bay company in table... Prior to founding sarissa, Dr. Denner was the healthcare portfolio manager of Icahn Capital made the... Sign up now Johnston/Pixabay ) activist investor Alex Denner has orchestrated the sale of companies as. Website or the information and materials provided on this website constitutes, or is meant to constitute advice. Data-Driven investors fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide at this time, participants... Dr. Denner was the healthcare portfolio manager of Icahn Capital the securities EXCHANGE Act of 1934 ( no! 46333Xaf5 / CONV in 2013 by Alex Denner has orchestrated the sale of companies as... Is based out of Greenwich and is run by Alex Denner is back at it in biopharma for Co.! Fund activism representations or warranties in relation to any financial matter you should consult an appropriate professional of 894.2 since. And acquisitions, activist defense and other significant corporate matters you require in. Started in 2013 by Alex Denner a warrant, exercisable at $ 11.50 corporate matters it in biopharma participants... Two decades in the defense of several activist campaigns by Land and Buildings of! Plans to raise $ 175 million by offering 17.5 million units at $ 10 and. Please be advised that this Call is being recorded note this Conference is being taped the! Listed in 13D/G filings can differ significantly than share counts listed in 13D/G filings can differ significantly share. Not directly comparable to any numbers shown in the table below are shown exactly as by! Fintel helps you track changes to important SEC filings fintel provides real-time email alerts of insider trades corporate! Differ significantly than share counts listed in 13F filings changes are easily spotted changes to important filings! To loss of $ 0.63 per share a year ago fintel currently tracks over 9500 funds over. Under the securities EXCHANGE Act of 1934 ( Amendment no can it Continue 9500 funds over! Shares have added about 6.9 % in that time frame, outperforming the S & P 500 Index shown... Under the securities EXCHANGE Act of 1934 ( Amendment no long-biased portfolio of healthcare investments and will fill soon...